Literature DB >> 12477695

Haploinsufficiency at the alpha-synuclein gene underlies phenotypic severity in familial Parkinson's disease.

Hirokazu Kobayashi1, Rejko Krüger, Katerina Markopoulou, Zbigniew Wszolek, Bruce Chase, Hikaru Taka, Reiko Mineki, Kimie Murayama, Olaf Riess, Yoshikuni Mizuno, Nobutaka Hattori.   

Abstract

To date, two point mutations, G209A and G88C, have been reported in the coding region of the alpha-synuclein gene in autosomal dominant familial Parkinson's disease. When translated, these lead to the missense mutations Ala53Thr and Ala30Pro, respectively. Reduced mRNA expression of the G209A allele was reported recently in a Greek-American family. Here, we show that alpha-synuclein mRNA is normally expressed in blood cells and report the results of an analysis of alpha-synuclein mRNA and protein expression in lymphoblastoid cell lines established from kindreds with the G209A and G88C mutations. mRNA expression was characterized using a TaqMan real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) assay. We assessed five affected and three unaffected members of a German family with the G88C mutation and two affected members in different, unrelated Greek families with the G209A mutation. The ratio of wild-type to mutant alpha-synuclein allele expression ranged from 2.2 to 9.2 in the affected individuals with a severe clinical phenotype. The ratios of the expression levels of the wild-type to mutant alleles were only slightly decreased in mild cases and were less than 1.0 in two asymptomatic heterozygotes. Sequence analysis of the RT-PCR products showed only the presence of G in position 88 and G in position 209 in severely affected heterozygotes of the German and Greek families, respectively. High performance liquid chromatography/mass spectrometry demonstrated that, relative to wild-type alpha-synuclein, there is a reduction of Ala30Pro alpha-synuclein in lymphoblastoid cell lines originating from severely affected, but not mildly affected G88C/+ heterozygotes. Taken together, these data indicate that there is haploinsufficiency at the alpha-synuclein gene and that the ratio of expression of the wild-type to mutant alleles correlates with the severity of the clinical phenotype. Furthermore, these findings suggest that haploinsufficiency of alpha-synuclein mutations may contribute to disease progression in these forms of familial Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12477695     DOI: 10.1093/brain/awg010

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  12 in total

1.  Biochemical and morphological consequences of human α-synuclein expression in a mouse α-synuclein null background.

Authors:  Kavita Prasad; Elizabeth Tarasewicz; Pamela A Ohman Strickland; Michael O'Neill; Stephen N Mitchell; Kalpana Merchant; Samnang Tep; Kathryn Hilton; Akash Datwani; Manuel Buttini; Sarah Mueller-Steiner; Eric K Richfield
Journal:  Eur J Neurosci       Date:  2011-01-28       Impact factor: 3.386

Review 2.  Neurodegenerative disorders: Parkinson's disease and Huntington's disease.

Authors:  S M Hague; S Klaffke; O Bandmann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-08       Impact factor: 10.154

Review 3.  Evolution of neurodegeneration.

Authors:  Mark R Cookson
Journal:  Curr Biol       Date:  2012-09-11       Impact factor: 10.834

4.  Lithium-responsive genes and gene networks in bipolar disorder patient-derived lymphoblastoid cell lines.

Authors:  M S Breen; C H White; T Shekhtman; K Lin; D Looney; C H Woelk; J R Kelsoe
Journal:  Pharmacogenomics J       Date:  2016-07-12       Impact factor: 3.550

5.  α-Synuclein is localized to mitochondria-associated ER membranes.

Authors:  Cristina Guardia-Laguarta; Estela Area-Gomez; Cornelia Rüb; Yuhui Liu; Jordi Magrané; Dorothea Becker; Wolfgang Voos; Eric A Schon; Serge Przedborski
Journal:  J Neurosci       Date:  2014-01-01       Impact factor: 6.167

Review 6.  Genetic variability in SNCA and Parkinson's disease.

Authors:  Lasse Pihlstrøm; Mathias Toft
Journal:  Neurogenetics       Date:  2011-07-29       Impact factor: 2.660

Review 7.  α-Synuclein in Parkinson's disease.

Authors:  Leonidas Stefanis
Journal:  Cold Spring Harb Perspect Med       Date:  2012-02       Impact factor: 6.915

8.  Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein.

Authors:  Wai Haung Yu; Yasuji Matsuoka; István Sziráki; Audrey Hashim; John Lafrancois; Henry Sershen; Karen E Duff
Journal:  Neurochem Res       Date:  2007-11-13       Impact factor: 3.996

Review 9.  Neurobiology of alpha-synuclein.

Authors:  Kostas Vekrellis; Hardy J Rideout; Leonidas Stefanis
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

10.  Neuroacanthocytosis associated with a defect of the 4.1R membrane protein.

Authors:  Antonio Orlacchio; Paolo Calabresi; Adriana Rum; Anna Tarzia; Anna Maria Salvati; Toshitaka Kawarai; Alessandro Stefani; Antonio Pisani; Giorgio Bernardi; Paolo Cianciulli; Patrizia Caprari
Journal:  BMC Neurol       Date:  2007-02-13       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.